Forward Citations = 30
Company Filing History:
Thomas Strüngmann, a German pharmaceutical entrepreneur, founded generic drug maker Hexal AG in 1986. His visionary leadership led to Hexal’s transformation into the second-largest generic drug maker in the country. In 2005, he and his twin brother Andreas sold Hexal to Novartis for a staggering $6.7 billion. Additionally, the Strüngmann brothers earned $8 billion from their stake in BioNTech SE, the German company that played a pivotal role in developing the Pfizer–BioNTech COVID-19 vaccine.
Get your Inventor Badge Today